Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $27.2 million.

  • Arcturus Therapeutics Holdings' Shares Outstanding (Weighted Average) rose 46.56% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 46.56%. This contributed to the annual value of $27.0 million for FY2024, which is 139.7% up from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Shares Outstanding (Weighted Average) stood at $27.2 million, which was up 46.56% from $27.1 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Shares Outstanding (Weighted Average) high stood at $27.2 million for Q3 2025, and its period low was $26376.0 during Q1 2022.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $22.5 million, with a median of $26.6 million in 2023.
  • In the last 5 years, Arcturus Therapeutics Holdings' Shares Outstanding (Weighted Average) tumbled by 9989.96% in 2022 and then surged by 10057864.73% in 2023.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Shares Outstanding (Weighted Average) stood at $26.3 million in 2021, then increased by 0.49% to $26.4 million in 2022, then grew by 0.69% to $26.6 million in 2023, then grew by 1.4% to $27.0 million in 2024, then grew by 0.7% to $27.2 million in 2025.
  • Its last three reported values are $27.2 million in Q3 2025, $27.1 million for Q2 2025, and $27.1 million during Q1 2025.